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Rubella virus, a pathogen from the Togaviridae fa m ily, 
is found solely in humans and causes rubella, a typi-
cal childhood disease. The virus is spread via air- 
borne droplets containing respiratory secretions 
from an infected person. Children with rubella present 
with maculopapular or macular rash and lymph node 
swelling. Infection in adults is usually more severe, 
and may be associated with bone and joint pain. The 
most severe form of infection is congenital rubella asso-
ciated with primary maternal infection during preg-
nancy. Conge nital rubella may contribute to vision 
defects, deafness, cardiac anomalies, microcephalia, 
developmental disorders, fetal death or infant mortal-
ity during the 1st year of life. Transfer of maternal anti-
bodies produced in res ponse to infection or immuniza-
tion protects fetus against rubella (Lambert et al., 2015; 
Murray et al., 2011).
Human herpesvirus 5 (HHV-5), referred to as human 
cytomegalovirus (CMV, HCMV), is a  lymphotropic 
virus from the Herpesviridae family, replicating in 
human fibroblasts, epithelial cells and macrophages. 
CMV establishes a latent infection in T-lymphocytes 
and macrophages. CMV may be spread with saliva, 
urine, breast milk, vaginal and cervical secretions, 
semen and blood. CMV infection may occur in utero; 
furthermore, the virus may be transmitted via oral and 
sexual route, during transfusions and organ transplan-
tations. In immunocompetent persons, the infection is 
typically asymptomatic or has the form of a mild mono-
nucleosis-like syndrome. However, it may become more 
severe in immunocompromised subjects or in patients 
on immunosuppressive treatment (Ludwig and Hengel, 
2009; Murray et al., 2011). Congenital CMV infection 
is considered to be the most common congenital trans-
missible disease in Europe. Primary maternal infec-
tion during pregnancy poses the highest risk of CMV 
transmission to the fetus. In seronegative women, the 
risk of primary infection approximates 1–8%, and in 
32% of the cases results in fetal transmission of CMV. 
Up to 10–18% of infected neonates develop congenital 
CMV infection which may manifest with impaired psy-
chomotor development, vision disorders, hearing loss 
or complete deafness. Whereas most of the infected 
neonates are asymptomatic at birth, 10–15% of them 
may develop late complications, typically hearing loss. 
Fetuses of seropositive women are usually protected by 
maternal CMV antibodies. However, even in such cases 
there is a 1.4% risk of fetal infection due to reactiva-
tion of a latent maternal infection with CMV or super-
infection with another viral strain, and up to 8% of 
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children infected in utero may suffer from hearing loss 
(Hamilton et al., 2014; Kadambari et al., 2011; Ludwig 
and Hengel, 2009).
The aim of the study was to analyze the seropreva-
lence of Rubella virus and cytomegalovirus antibodies 
among young women. The study included 175 healthy 
women from the Biała Podlaska District (Lublin Pro-
vince, Poland), aged between 16 and 35 years (mean age 
22.7 years). Women living in towns and villages consti-
tuted 46% (n = 80) and 54% (n = 95) of the study group, 
respectively. Fifty six (32%) study subjects declared 
having higher education; 118 (67%) women had com-
pleted secondary and 1 (1%) primary education. Blood 
samples were collected in May 2015. 
The presence of anti-Rubella virus IgG was detected 
by ELISA (Anti-Rubella virus ELISA (IgG), Euroim-
mun, Germany). Microtiter wells were coated with 
antigens of Rubella virus. The results above or equal 
11 relative units/ml (RU/ml) were considered as posi-
tive, below 8 RU/ml as negative, whereas borderline 
results were ≥ 8 and < 11 RU/ml. The presence of 
anti-CMV IgG was detected by ELISA (Anti-CMV 
ELISA (IgG), Euroimmun, Germany). Microtiter wells 
were coated with antigens of CMV. The results above 
or equal 22 RU/ml were considered as positive, below 
16 RU/ml as negative, whereas borderline results were 
≥ 16 and < 22 RU/ml. The tests were carried out and 
the results were interpreted according to the manufac-
turer’s instructions.
The results were subjected to statistical analysis 
with Statistica v. 10 package. Significant differences 
in values of quantitative variables were identified with 
non-parametric Mann-Whitney U-test, with statis-
tical significance threshold set at p = 0.05. The study 
protocol was approved by the Local Bioethics Com-
mittee at the Medical University of Lublin (decision 
no. KE-0254/183/2014).
One hundred seventy two (98.3%) study subjects 
tested positive for rubella antibodies, 1 (0.6%) was sero-
indeterminate and 2 (1.1%) were seronegative. CMV 
antibodies were detected in 119 (68.0%) participants; 
the series included also 1 (0.6%) seroindeterminate 
subject and 55 (31.4%) seronegative women. Detailed 
information about the antibody levels is presented in 
Table I. The levels of rubella and CMV antibodies were 
not significantly affected by age, place of residence and 
educational level of the study subjects.
According to the ECDC report on epidemiology 
of mumps and rubella, a total of 1 708 rubella cases 
were recorded in Europe between July 2015 and June 
2016, and the vast majority of them (n = 1 553, 91%) 
were diagnosed in Poland. However, as emphasized by 
the authors of the report, only a very small propor-
tion of the diagnoses (1.1%) were confirmed in a labo-
ratory setting (ECDC 2016). In 1989–2002, active 
immunization with a monovalent rubella vaccine was 
obligatory solely for Polish girls. However, beginning 
in 2003, all Polish children, both girls and boys, need 
to be immunized with two doses of MMR (measles, 
mumps, rubella) combined vaccine at 2 and 10 years of 
age (Zimmerman et al., 2011). According to the report 
published by the National Institute of Hygiene, MMR 
vaccination coverage in Poland is high, exceeding 95% 
in 2015 (Czarkowski et al., 2015). Smits et al. (2014) 
presented a 32-year Dutch experience with MMR 
vaccine; the product proved to be effective, as long-
term persistence of antibodies induced by vaccination 
was demonstrated in up to 95% of subjects who had 
received two doses of MMR.
The study conducted in 2000–2002 by Wysokińska 
et al. (2004) in a group of 15- to 30-year-old women 
(n = 1 289) from various regions of Poland, documented 
the presence of anti-rubella IgG > 15 IU/ml in 89.5% 
of the subjects. Also 98.3% of women participating 
in our study had rubella antibody levels ≥ 11 RU/ml. 
Currently, ≥ 10 IU/ml is considered a protective level of 
rubella antibodies (Lambert et al., 2015). In view of the 
abovementioned findings, a considerable proportion 
of Polish children diagnosed with rubella solely on the 
basis of clinical presentation, may in fact suffer from 
other viral diseases that manifest with maculopapular 
rash, e.g. parvovirus B19 infection.
≤ 19 17 55.78 24.42 10.40 97.09 59.53 60.89 < 2.00 167.78
20–21 73 82.48 53.21 6.96 > 200.00 77.02 62.92 < 2.00 > 200.00
22–23 40 76.34 48.18 5.09 > 200.00 77.58 64.63 < 2.00 > 200.00
24–25 14 117.14 63.63 29.00 > 200.00 85.94 69.81 < 2.00 > 200.00
26–27 10 87.18 53.04 20.93 191.93 63.89 71.81 < 2.00 199.14
≥ 28 21 98.02 60.46 11.21 > 200.00 104.13 75.23 < 2.00 > 200.00
Total 175 83.39 53.10 5.09 > 200.00 78.67 65.79 < 2.00 > 200.00
Table I
Titers of anti-Rubella virus and anti-CMV IgG depending on age
Age Numberof persons (N)
Titers of anti-Rubella virus (RU/ml) Titers of anti-CMV (RU/ml)
SDx– MIN MAX SDx– MIN MAX
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The seroprevalence of CMV antibodies among 
women of childbearing age ranges between 45% and 
100%. The highest seroprevalence is reported in Africa, 
Asia and South America, and the lowest in Western 
Europe and United States. The seroprevalence increases 
with age; furthermore, it was shown to be higher in 
individuals with poor socioeconomic status and in non-
white women (Cannon et al., 2010). The seropreva- 
lence of CMV antibodies in European women of 
childbearing age varies between 30% and 96%. The low-
est seroprevalence rates were documented in Ireland 
(in native Irish women), Netherlands and Germany, 
and the highest in Turkey, United Kingdom in Asian 
women and Ireland in non-Irish immigrants (Ludwig 
and Hengel, 2009).
Gaj et al. (2012) analyzed the seroprevalence of CMV 
antibodies in pregnant women who have been hospital-
ized in two clinics in Łódź in 1999–2009. Anti-CMV 
IgG and IgM were detected in 76.7% and 13% of the 
study subjects, respectively. The seroprevalence of CMV 
antibodies was not influenced by age, parity and place 
of residence; however, anti-CMV IgG were detected 
less often in women examined in 2005–2009 than in 
those tested during the earlier period. In another study, 
conducted in 2010–2011, also among pregnant women 
from two hospitals in Łódź, Wujcicka et al. (2014) 
documented a 62.4% seroprevalence of anti-CMV IgG. 
The CMV antibodies were significantly more often 
found in women aged 36 years and older, with primary 
or vocational education, and in those having children. 
Siennicka et al. (2016) analyzed sera from 712 women 
aged between 15 and 49  years, and showed that the 
seroprevalence of CMV antibodies increased with age, 
from 74.3% in subjects younger than 30 years, to 94.3% 
in those older than 45 years. The seroprevalence was not 
affected by the place of residence of the study subjects. 
In our present study, the seroprevalence of anti-CMV 
IgG amounted to 68.0%. We did not observe statisti-
cally significant age-related differences in the antibody 
levels, probably due the fact that all the study subjects 
were younger than 36 years and most of them (92%) 
had no children. Nevertheless, these findings imply that 
Poland is a country with a moderate seroprevalence 
of CMV antibodies.
In conclusion, this study documented the high, up 
to 98.3% seroprevalence of rubella antibodies, which 
seems to confirm the effectiveness of the vaccination 
program that is currently used in Poland. 68.0% of 
the study subjects tested positively for anti-CMV IgG, 
which implies that Poland is a country with a moderate 
seroprevalence of cytomegalovirus antibodies.
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